{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:38:01Z","timestamp":1784043481512,"version":"3.55.0"},"reference-count":44,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:p>\n                    Drugs used to treat psychiatric disorders, although effective, are often restricted by adverse events. The use of partial agonists for treating hypertension was found to limit some of the side-effects in some patients. This led to the investigation of partial agonists as a treatment modality in psychiatric disorders. Partial agonists have a lower intrinsic efficacy than full agonists leading to reduced maximum response. They can act as antagonists by competing for receptor binding with full agonists. The level of activity depends on the level of endogenous receptor activity. Buprenorphine, a partial agonist at the mu-opioid receptor, is used to treat patients with addiction and decreases the symptoms of withdrawal and risks of overdose and intoxication. The anxiolytic buspirone shows partial agonism at 5-HT\n                    <jats:sub>1A<\/jats:sub>\n                    receptors, and this seems to provide anxioselective effects, without inducing extrapyramidal side-effects, convulsions, tolerance or withdrawal reactions. In schizophrenia, partial dopamine agonism results in antagonistic effects at sites activated by high concentrations of dopamine and agonistic effects at sites activated by low concentrations of dopamine. This stabilizes the dopamine system to effect antipsychotic action without inducing adverse motor or hormonal events. Aripiprazole is the first \u2018dopamine system stabilizer\u2019, and the data are promising, with efficacy at least equivalent to that with current atypical antipsychotics but fewer of the troublesome side-effects. Partial agonists seem to provide a way to fine-tune the treatment of psychiatric disorders by maximizing the treatment effect while minimizing undesirable adverse events.\n                  <\/jats:p>","DOI":"10.1177\/0269881105053308","type":"journal-article","created":{"date-parts":[[2005,6,27]],"date-time":"2005-06-27T13:21:06Z","timestamp":1119878466000},"page":"408-413","source":"Crossref","is-referenced-by-count":59,"title":["The place of partial agonism in psychiatry: recent developments"],"prefix":"10.1177","volume":"19","author":[{"given":"R. I.","family":"Ohlsen","sequence":"first","affiliation":[{"name":"Institute of Psychiatry, De Crespigny Park, London, UK.,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. S.","family":"Pilowsky","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, De Crespigny Park, London, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2005,7,1]]},"reference":[{"key":"atypb1","volume-title":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"Baldessarini R J","year":"1996"},{"key":"atypb2","unstructured":"Bristol-Myers Squibb (2000) Buspar, Data Sheet"},{"key":"atypb3","unstructured":"Bristol-Myers Squibb and Otsuka Pharmaceuticals (2004) Abilify, Prescribing Information"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.033175"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(94)00129-N"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(88)90012-7"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1344-3"},{"key":"atypb8","first-page":"185","volume":"5","author":"Cornblatt B","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(03)00146-9"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.148.11.1474"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(00)80320-X"},{"key":"atypb12","volume-title":"New York, NY: Medscape Presented at the National Medical Association 2003 Annual Convention and Scientific Assembly","author":"Franklin J E"},{"issue":"2","key":"atypb13","first-page":"24","volume":"64","author":"Gorman J M","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(98)00023-5"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1038\/nn1091"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01532-7"},{"key":"atypb17","volume-title":"Psychopharmacology: the Fourth Generation of Progress","author":"Kahn R S","year":"1995"},{"key":"atypb18","first-page":"325","volume":"6","author":"Kasper S","year":"2003","journal-title":"haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2004.02.012"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(97)00030-9"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050079"},{"issue":"1","key":"atypb22","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.3109\/13651509809115108","volume":"2","author":"Leysen J E","year":"1998","journal-title":"Int J Psychiatry Clin Pract"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418040-00005"},{"issue":"1","key":"atypb24","first-page":"S186","volume":"5","author":"Lieberman J A","year":"2002","journal-title":"Int J Neuropsychopharmacology"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(00)80321-1"},{"key":"atypb26","volume-title":"American Psychiatric Association 156th Annual Meeting","author":"McQuade R D"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(03)00050-1"},{"key":"atypb28","first-page":"69","author":"Nash M","year":"1997","journal-title":"Time"},{"key":"atypb29","volume-title":"Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia","author":"National Institute for Clinical Excellence","year":"2002"},{"key":"atypb30","volume-title":"Innovative Psychopharmacotherapy","author":"Neppe V M","year":"1990"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0910"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.7.681"},{"key":"atypb33","volume-title":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"Reisine T","year":"1996"},{"key":"atypb34","first-page":"29","volume":"68","author":"Richelson E","year":"2000","journal-title":"Focus on newer generation compounds. Life Sci"},{"issue":"14","key":"atypb35","first-page":"9","volume":"63","author":"Rickels K","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"atypb36","volume-title":"Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics","author":"Ross E M","year":"1996"},{"key":"atypb37","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)53442-6"},{"key":"atypb38","volume-title":"Psychosis and schizophrenia. In Essential Psychopharmacology: Neuroscientific Basis and Practical Applications","author":"Stahl S M","year":"2000"},{"key":"atypb39","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1101"},{"issue":"1","key":"atypb40","first-page":"S186","volume":"5","author":"Stock E","year":"2002","journal-title":"Int J Neuropsychopharmacology"},{"key":"atypb41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1742-1241.2003.tb11397.x","volume":"57","author":"Taylor D M","year":"2003","journal-title":"Int J Clin Pract"},{"key":"atypb42","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(00)80319-3"},{"key":"atypb43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01154.x"},{"key":"atypb44","doi-asserted-by":"publisher","DOI":"10.1038\/386827a0"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881105053308","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881105053308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:09:21Z","timestamp":1777507761000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881105053308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1177\/0269881105053308"],"URL":"https:\/\/doi.org\/10.1177\/0269881105053308","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}